PNCA
MCID: PNC035
MIFTS: 87

Pancreatic Cancer (PNCA)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer 57 12 73 20 72 36 13 54 42 15 37
Pancreatic Carcinoma 57 12 20 72 54 44 15 17 70
Familial Pancreatic Carcinoma 20 58 29 6
Pancreatic Carcinoma, Familial 12 73 70
Carcinoma of Pancreas 12 29 6
Pancreatic Neoplasm 12 17 70
Malignant Neoplasm of Pancreas 70 32
Pancreatic Acinar Carcinoma 57 72
Familial Pancreatic Cancer 20 58
Cancer of the Pancreas 20 6
Pancreatic Neoplasms 6 44
Pancreatic Tumor 12 54
Malignant Neoplasm of Body of Pancreas 12
Malignant Neoplasm of Head of Pancreas 12
Malignant Neoplasm of Tail of Pancreas 12
Pancreatic Cancer, Susceptibility to 6
Hereditary Pancreatic Carcinoma 20
Pancreatic Carcinoma, Somatic 57
Carcinoma of Head of Pancreas 6
Hereditary Pancreatic Cancer 20
Exocrine Pancreas Carcinoma 12
Pancreatic Cancer, Somatic 57
Neoplasm of the Pancreas 29
Ca Body of Pancreas 12
Ca Head of Pancreas 12
Ca Tail of Pancreas 12
Pancreas Carcinoma 20
Cancer, Pancreatic 39
Pancreas Neoplasm 12
Pancreatic Tumors 15
Exocrine Cancer 12
Pancreas Cancer 20
Pnca 72

Characteristics:

Orphanet epidemiological data:

58
familial pancreatic carcinoma
Inheritance: Multigenic/multifactorial; Age of onset: Adult;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
somatic mutation
autosomal dominant
multifactorial

Miscellaneous:
may be seen with other forms of cancer in a family


HPO:

31
pancreatic cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:1793 DOID:4905
OMIM® 57 260350
KEGG 36 H00019
NCIt 50 C3305 C3850
MESH via Orphanet 45 C535837
ICD10 via Orphanet 33 C25
UMLS via Orphanet 71 C2931038
Orphanet 58 ORPHA1333
MedGen 41 C0235974
UMLS 70 C0030297 C0153458 C0153459 more

Summaries for Pancreatic Cancer

GARD : 20 Familial pancreatic cancer (FPC) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). It is sometimes referred to as FPC only when there is not a known hereditary cancer syndrome in an affected family. In familial cases, pancreatic cancer often occurs before age 50 (earlier than other forms of pancreatic cancer). In 60% of cases it occurs within the head of the pancreas. Symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. Pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. A specific genetic cause of FPC (in the absence of a known syndrome ) has not been identified. Familial cases of pancreatic cancer due to hereditary conditions may be caused by mutations in any of several genes. Individuals who carry a mutation in one of these genes are often at an increased risk of other types of cancers as well. Currently, only 10-20% of families with FPC will have a mutation identified by genetic testing. Hereditary cancer syndromes and other inherited conditions associated with pancreatic cancer include: BRCA1 hereditary breast and ovarian cancer syndrome BRCA2 hereditary breast and ovarian cancer syndrome Peutz-Jeghers syndrome FAMMM syndrome Lynch syndrome Hereditary pancreatitis In many cases, inheritance of FPC is autosomal dominant ; in some cases, is may be multifactorial. It is important to note that pancreatic cancer itself is not inherited, but a genetic predisposition to developing cancer is inherited. Treatment may include surgical resection, chemotherapy, and/or radiotherapy. Resection is the only potential cure, but most patients have advanced, non-resectable tumors by the time of diagnosis.

MalaCards based summary : Pancreatic Cancer, also known as pancreatic carcinoma, is related to pancreatic ductal adenocarcinoma and dysplastic nevus syndrome, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Pancreatic cancer and PI3K-Akt signaling pathway. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, liver and breast, and related phenotypes are pancreatic adenocarcinoma and exocrine pancreatic insufficiency

Disease Ontology : 12 An endocrine gland cancer located in the pancreas.

OMIM® : 57 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350) (Updated 20-May-2021)

MedlinePlus : 42 The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

KEGG : 36 Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.

UniProtKB/Swiss-Prot : 72 Pancreatic cancer: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Wikipedia : 73 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4
Pancreatic Cancer 5

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1207)
# Related Disease Score Top Affiliating Genes
1 pancreatic ductal adenocarcinoma 33.8 TP53 SMAD4 MIR483 MIR221 MIR21 MIR15A
2 dysplastic nevus syndrome 33.8 STK11 PALB2 BRCA2 BRCA1 ATM
3 hereditary breast ovarian cancer syndrome 33.3 TP53 STK11 PALB2 KRAS BRCA2 BRCA1
4 pancreatic adenocarcinoma 33.3 TP53 SMAD4 KRAS BRCA2
5 adenocarcinoma 33.3 TP53 STK11 SMAD4 KRAS BRCA2 BRCA1
6 pancreatic signet ring cell adenocarcinoma 32.8 TP53 KRAS
7 malignant exocrine pancreas neoplasm 32.7 TP53 SMAD4 KRAS
8 islet cell tumor 32.7 PALB2 MIR483 BRCA2
9 pancreas disease 32.7 TP53 MIR483 MIR34A MIR221 MIR21 MIR17
10 breast cancer 32.7 TSC1 TP53 STK11 SMAD4 RBBP8 PALB2
11 lynch syndrome 32.6 TP53 STK11 SMAD4 PALB2 MIR17 KRAS
12 breast-ovarian cancer, familial 2 32.5 BRCA2 BRCA1
13 ovarian cancer 32.4 TP53 STK11 SMAD4 PALB2 MIR34A MIR221
14 gastric cancer 32.4 TP53 SMAD4 MIR34A MIR221 MIR21 MIR17
15 colorectal cancer 32.3 TP53 STK11 SMAD4 PALB2 MIR483 MIR34A
16 melanoma 32.3 TP53 STK11 MIR34A MIR221 MIR17 MIR15A
17 ataxia-telangiectasia 32.2 TP53 STK11 BRCA2 BRCA1 ATM
18 b-cell lymphoma 32.2 TP53 MIR34A MIR21 MIR17 MIR155 ATM
19 peutz-jeghers syndrome 32.1 TSC1 TP53 STK11 SMAD4 BRCA2
20 body mass index quantitative trait locus 11 32.1 MIR483 MIR34A MIR221 MIR21 MIR17 MIR155
21 cholangiocarcinoma 32.1 TP53 SMAD4 MIR21 KRAS
22 melanoma, cutaneous malignant 1 32.1 TP53 STK11 PALB2 BRCA2 BRCA1 ATM
23 bile duct cancer 32.1 TP53 STK11 SMAD4 MIR21 MIR17 KRAS
24 li-fraumeni syndrome 32.1 TP53 STK11 SMAD4 PALB2 MIR483 KRAS
25 lung cancer 32.1 TP53 STK11 SMAD4 MIR483 MIR34A MIR221
26 in situ carcinoma 32.0 TP53 MIR17 BRCA2 BRCA1
27 bladder cancer 32.0 TSC1 TP53 MIR34A MIR221 MIR21 MIR17
28 esophageal cancer 31.9 TP53 SMAD4 MIR483 MIR34A MIR21 KRAS
29 lung cancer susceptibility 3 31.9 TP53 STK11 SMAD4 MIR483 MIR21 MIR17
30 glioblastoma 31.9 TP53 MIR34A MIR221 MIR21 MIR155 BRCA2
31 peripheral nervous system disease 31.9 TP53 MIR483 MIR34A MIR21 MIR17
32 papillary adenocarcinoma 31.9 TP53 MIR21 KRAS BRCA2 BRCA1
33 fanconi anemia, complementation group a 31.9 TP53 RBBP8 PALB2 BRCA2 BRCA1 ATM
34 intrahepatic cholangiocarcinoma 31.8 TP53 SMAD4 KRAS
35 acinar cell carcinoma 31.8 TP53 STK11 SMAD4 BRCA2
36 gastrointestinal system disease 31.8 MIR483 MIR34A MIR221 MIR21 MIR17 MIR15A
37 endometrial cancer 31.7 TP53 STK11 SMAD4 MIR34A KRAS BRCA2
38 prostate cancer 31.7 TP53 SMAD4 MIR34A MIR221 MIR21 MIR17
39 skin carcinoma 31.7 TP53 STK11 MIR34A MIR21 MIR17 KRAS
40 non-alcoholic fatty liver disease 31.7 TP53 MIR34A MIR21 MIR17 MIR155
41 rectum cancer 31.7 MIR483 MIR21 MIR17 KRAS
42 adenosquamous carcinoma 31.7 TP53 SMAD4 KRAS
43 adenoma 31.6 TSC1 TP53 SMAD4 KRAS
44 breast ductal carcinoma 31.6 TP53 SMAD4 MIR17 BRCA2 BRCA1
45 leukemia, chronic lymphocytic 31.6 TP53 MIR483 MIR34A MIR221 MIR21 MIR17
46 hepatocellular carcinoma 31.6 TSC1 TP53 SMAD4 MIR483 MIR34A MIR221
47 leukemia, acute myeloid 31.6 TP53 MIR483 MIR34A MIR221 MIR21 MIR17
48 renal cell carcinoma, nonpapillary 31.5 TSC1 TP53 MIR34A MIR221 MIR21 MIR17
49 gallbladder disease 31.5 TSC1 TP53 MIR483 MIR17 KRAS
50 glioma 31.5 TP53 MIR34A MIR221 MIR21 MIR17 MIR15A

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Cholangitis
Cholestasis Deficiency Anemia
Intestinal Obstruction Pancreatic Agenesis 1
Pancreatitis, Hereditary Protein-Energy Malnutrition
Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Human phenotypes related to Pancreatic Cancer:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pancreatic adenocarcinoma 58 31 obligate (100%) Obligate (100%) HP:0006725
2 exocrine pancreatic insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0001738
3 back pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0003418
4 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
5 anorexia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002039
6 chronic fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012432
7 weight loss 58 31 hallmark (90%) Very frequent (99-80%) HP:0001824
8 poor appetite 58 31 hallmark (90%) Very frequent (99-80%) HP:0004396
9 jaundice 58 31 frequent (33%) Frequent (79-30%) HP:0000952
10 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
11 intestinal pseudo-obstruction 58 31 frequent (33%) Frequent (79-30%) HP:0004389
12 extrahepatic cholestasis 58 31 frequent (33%) Frequent (79-30%) HP:0012334
13 functional intestinal obstruction 58 31 frequent (33%) Frequent (79-30%) HP:0005249
14 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
15 diabetes mellitus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000819
16 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
17 melanoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002861
18 colon cancer 58 31 occasional (7.5%) Occasional (29-5%) HP:0003003
19 breast carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0003002
20 neoplasm of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0002896
21 intermittent diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002254
22 hepatosplenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001433
23 ovarian carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0025318
24 peritoneal abscess 58 31 occasional (7.5%) Occasional (29-5%) HP:0100592
25 neoplasm of the pancreas 31 HP:0002894
26 increased level of l-fucose in urine 31 HP:0410067

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Abdomen Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma

Clinical features from OMIM®:

260350 (Updated 20-May-2021)

UMLS symptoms related to Pancreatic Cancer:


nausea and vomiting; constipation; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 9.53 BRCA1 RBBP8
2 Decreased homologous recombination repair frequency GR00151-A-2 9.53 BRCA1 RBBP8
3 Decreased homologous recombination repair frequency GR00236-A-1 9.53 BRCA1 BRCA2 PALB2 RBBP8
4 Decreased homologous recombination repair frequency GR00236-A-2 9.53 BRCA1 BRCA2 PALB2 RBBP8
5 Decreased homologous recombination repair frequency GR00236-A-3 9.53 BRCA1 BRCA2 PALB2 RBBP8

MGI Mouse Phenotypes related to Pancreatic Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 ACVR1B ATM BRCA1 BRCA2 KRAS PALB2
2 embryo MP:0005380 9.9 ACVR1B ATM BRCA1 BRCA2 KRAS PALB2
3 integument MP:0010771 9.65 ACVR1B ATM BRCA1 BRCA2 KRAS PALB2
4 neoplasm MP:0002006 9.32 ATM BRCA1 BRCA2 KRAS PALB2 RBBP8

Drugs & Therapeutics for Pancreatic Cancer

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 629)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
5
Desflurane Approved Phase 4 57041-67-5 42113
6
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
7
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
8
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
9
Thrombin Approved, Investigational Phase 4
10
Levodopa Approved Phase 4 59-92-7 6047
11
Pasireotide Approved Phase 4 396091-73-9 9941444
12
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
13
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
15
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
17
Morphine Approved, Investigational Phase 4 57-27-2 5288826
18
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
19
Lysine Approved, Nutraceutical Phase 4 56-87-1 5962
20
Nimotuzumab Investigational Phase 4 780758-10-3, 828933-61-3
21 Parenteral Nutrition Solutions Phase 4
22 Soy Bean Phase 4
23 Fibrin Tissue Adhesive Phase 4
24 Soybean oil, phospholipid emulsion Phase 4
25 Fat Emulsions, Intravenous Phase 4
26 Anesthetics Phase 4
27 Nicotinic Agonists Phase 4
28 Dopamine Agents Phase 4
29 Dopamine Uptake Inhibitors Phase 4
30 Adrenergic Agents Phase 4
31 Anesthetics, General Phase 4
32 Hypnotics and Sedatives Phase 4
33 Anesthetics, Inhalation Phase 4
34 Adrenergic alpha-Agonists Phase 4
35 Adrenergic Agonists Phase 4
36 Pharmaceutical Solutions Phase 4
37 Coagulants Phase 4
38 Dihydroxyphenylalanine Phase 4
39 Hormone Antagonists Phase 4
40 Anti-Inflammatory Agents Phase 4
41 Hydrocortisone 17-butyrate 21-propionate Phase 4
42 Hydrocortisone hemisuccinate Phase 4
43 Analgesics Phase 4
44 Psychotropic Drugs Phase 4
45 Anti-Anxiety Agents Phase 4
46 Anticonvulsants Phase 4
47 Analgesics, Opioid Phase 4
48 calcium channel blockers Phase 4
49
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
50
Nadroparin Approved, Investigational Phase 3

Interventional clinical trials:

(show top 50) (show all 2372)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
3 Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
4 The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy Unknown status NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
5 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
6 A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment Unknown status NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
7 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
8 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Unknown status NCT03642093 Phase 4
9 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
10 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
11 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
12 Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study Completed NCT01041612 Phase 4
13 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
14 A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
15 The Importance of Albumin Infusion Rate for Plasma Volume Expansion. AIR. A Phase III Assessor Blinded Parallel Group Randomized Study Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
16 Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
17 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
18 Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment. Completed NCT00966277 Phase 4 Dalteparin
19 A Prospective Study of Celiac Block Technique: One Injection or Two? Completed NCT00583479 Phase 4
20 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
21 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
22 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
23 Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
24 Randomized Controlled Study to Evaluate the Effect of Thrombin-containing Collagen-based Hemostatic Matrix on Prevention of Pancreatic Fistula After Pancreatecomy Recruiting NCT04357483 Phase 4 flowable thrombin containing collagen hemostat matrix;thrombin coated L-dopa contained collagen patch
25 Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects Recruiting NCT03859869 Phase 4 Pancrelipase;Placebo
26 Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery Recruiting NCT04025840 Phase 4 Dexamethasone
27 Endoscopic Ultrasound Guided Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Intractable Pain Due to Malignancy A Randomized Controlled Study Recruiting NCT04809935 Phase 4 98% dehydrated alcohol
28 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
29 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
30 A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Active, not recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
31 HYPAR Trial - Hydrocortisone vs Pasireotide in Reducing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial Active, not recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
32 A Single-arm, Prospective Study to Evaluate the Efficacy and Safety of the Combination of Paclitaxel Liposome and S-1 as First-line Therapy in Treating Patients With Advanced Metastatic Pancreatic Cancer Not yet recruiting NCT04217096 Phase 4 Paclitaxel liposome;S-1
33 A Phase 4 Open-Label Single-Arm Study To Evaluate The Use Of CREON In Subjects With EPI Due To Etiologies Other Than Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer Not yet recruiting NCT04315311 Phase 4 CREON
34 Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity Not yet recruiting NCT04269369 Phase 4 5-Fluorouracil
35 An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
36 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
37 Quality of Life After Bilioenteric Anastomosis in Comparison to Endoscopically Placed Stents in Patients With Unresectable Pancreatic Cancer and Jaundice Terminated NCT01887041 Phase 4
38 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn NCT03891979 Phase 4 Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
39 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
40 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
41 A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH) Unknown status NCT01077427 Phase 3 Gemcitabine + Capecitabine
42 Randomized Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer Unknown status NCT00440167 Phase 3 Gemcitabine;Capecitabine;Erlotinib
43 CROSSFIRE Trial: Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival After Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation Unknown status NCT02791503 Phase 2, Phase 3
44 Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas. Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
45 A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing. Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
46 Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
47 Comparison of Resection During Distal Pancreatectomy of the Splenic Vein Either Together With the Pancreatic Parenchyma or After Isolation: A Multicentre, Prospective, Randomized Phase III Trial Unknown status NCT02871804 Phase 3
48 A Prospective RCT Study of Distal Pancreatectomy Combined With Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail Unknown status NCT02117895 Phase 3
49 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
50 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3 Gemcitabine;Curcumin;Celebrex

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


docetaxel
Fluorouracil
Ifosfamide
irinotecan
Irinotecan hydrochloride
Octreotide
Octreotide Acetate
sunitinib
sunitinib malate
Tamoxifen
Tamoxifen Citrate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Pancreas 29 KRAS SMAD4 STK11 TP53
2 Neoplasm of the Pancreas 29
3 Familial Pancreatic Carcinoma 29

Anatomical Context for Pancreatic Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Cancer:

19
Pancreas

MalaCards organs/tissues related to Pancreatic Cancer:

40
Pancreas, Liver, Breast, T Cells, Lymph Node, Endothelial, Colon
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 35608)
# Title Authors PMID Year
1
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. 6 57 54 61
18762988 2008
2
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 61 57 6
25356972 2015
3
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. 6 61 54
11248065 2001
4
DPC4 gene in various tumor types. 54 61 6
8653691 1996
5
MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. 57 61 54
7845688 1995
6
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. 54 61 57
7726912 1994
7
p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. 54 61 6
8513440 1993
8
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. 61 57
32376951 2020
9
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. 57 61
31221853 2019
10
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. 61 57
30996350 2019
11
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. 57 61
30918400 2019
12
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. 61 57
28099419 2017
13
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. 57 61
27732578 2016
14
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. 61 57
27213290 2016
15
Genomic analyses identify molecular subtypes of pancreatic cancer. 57 61
26909576 2016
16
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. 57 61
26168401 2015
17
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. 61 57
26106858 2015
18
Whole genomes redefine the mutational landscape of pancreatic cancer. 61 57
25719666 2015
19
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. 61 57
23535601 2013
20
Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer. 6 61
23561644 2013
21
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. 57 61
23103869 2012
22
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. 61 57
22368299 2012
23
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. 61 57
21436454 2011
24
mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. 6 61
21189378 2011
25
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. 57 61
20981101 2010
26
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. 61 57
20981102 2010
27
Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). 6 61
20581473 2010
28
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. 61 57
20101243 2010
29
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. 57 61
19648918 2009
30
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. 61 47 54
19714243 2009
31
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. 61 57
19460966 2009
32
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. 61 6
19264984 2009
33
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. 54 61 47
19407485 2009
34
The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. 61 6
17415588 2007
35
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. 61 6
17194196 2006
36
Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. 61 57
15912495 2005
37
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. 57 61
14520413 2003
38
Progression model for pancreatic cancer. 57 61
10955772 2000
39
Inheritance of pancreatic cancer in pancreatic cancer-prone families. 57 61
10872424 2000
40
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. 61 6
10362809 1999
41
Characterization of a carboxy-terminal BRCA1 interacting protein. 6 61
9811458 1998
42
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. 61 57
9091646 1997
43
Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. 61 57
7666917 1995
44
Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. 57 61
7616537 1995
45
Medical genetic study of eight pancreatic cancer-prone families. 57 61
7874567 1995
46
Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. 61 6
8439212 1993
47
Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. 57 61
3828965 1987
48
Pancreatic cancer in father and son. 57 61
67325 1977
49
Familial carcinoma of the pancreas. 61 57
1269168 1976
50
Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer. 42 61
33761652 2021

Variations for Pancreatic Cancer

ClinVar genetic disease variations for Pancreatic Cancer:

6 (show top 50) (show all 370)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PALB2 NM_024675.3(PALB2):c.3256C>T (p.Arg1086Ter) SNV Pathogenic, risk factor 126729 rs587776527 GRCh37: 16:23619279-23619279
GRCh38: 16:23607958-23607958
2 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 GRCh37: 13:32954050-32954050
GRCh38: 13:32379913-32379913
3 BRCA2 NM_000059.3(BRCA2):c.6408_6414del (p.Asn2137fs) Deletion Pathogenic 52086 rs397507851 GRCh37: 13:32914898-32914904
GRCh38: 13:32340761-32340767
4 PALB2 NM_024675.3(PALB2):c.2509G>T (p.Glu837Ter) SNV Pathogenic 241546 rs587778587 GRCh37: 16:23640966-23640966
GRCh38: 16:23629645-23629645
5 BRCA2 NM_000059.4(BRCA2):c.5682C>G (p.Tyr1894Ter) SNV Pathogenic 37989 rs41293497 GRCh37: 13:32914174-32914174
GRCh38: 13:32340037-32340037
6 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
7 BRCA1 NM_007294.4(BRCA1):c.4327C>T (p.Arg1443Ter) SNV Pathogenic 17675 rs41293455 GRCh37: 17:41234451-41234451
GRCh38: 17:43082434-43082434
8 PALB2 NM_024675.3(PALB2):c.2288_2291del (p.His762_Leu763insTer) Deletion Pathogenic 232125 rs876659571 GRCh37: 16:23641184-23641187
GRCh38: 16:23629863-23629866
9 BRCA2 NM_000059.4(BRCA2):c.5857G>T (p.Glu1953Ter) SNV Pathogenic 51952 rs80358814 GRCh37: 13:32914349-32914349
GRCh38: 13:32340212-32340212
10 PALB2 NM_024675.4(PALB2):c.1240C>T (p.Arg414Ter) SNV Pathogenic 128117 rs180177100 GRCh37: 16:23646627-23646627
GRCh38: 16:23635306-23635306
11 BRCA2 NM_000059.4(BRCA2):c.145G>T (p.Glu49Ter) SNV Pathogenic 51129 rs80358435 GRCh37: 13:32893291-32893291
GRCh38: 13:32319154-32319154
12 PALB2 NM_024675.3(PALB2):c.3549C>A (p.Tyr1183Ter) SNV Pathogenic 128144 rs118203998 GRCh37: 16:23614792-23614792
GRCh38: 16:23603471-23603471
13 PALB2 NM_024675.3(PALB2):c.2167_2168del (p.Met723fs) Deletion Pathogenic 136132 rs587776416 GRCh37: 16:23641307-23641308
GRCh38: 16:23629986-23629987
14 BRCA2 NM_000059.4(BRCA2):c.92G>A (p.Trp31Ter) SNV Pathogenic 52808 rs397508045 GRCh37: 13:32893238-32893238
GRCh38: 13:32319101-32319101
15 BRCA2 NM_000059.4(BRCA2):c.100G>T (p.Glu34Ter) SNV Pathogenic 51041 rs80358391 GRCh37: 13:32893246-32893246
GRCh38: 13:32319109-32319109
16 BRCA2 NM_000059.4(BRCA2):c.3109C>T (p.Gln1037Ter) SNV Pathogenic 37819 rs80358557 GRCh37: 13:32911601-32911601
GRCh38: 13:32337464-32337464
17 BRCA2 NM_000059.4(BRCA2):c.4965C>G (p.Tyr1655Ter) SNV Pathogenic 37936 rs80358721 GRCh37: 13:32913457-32913457
GRCh38: 13:32339320-32339320
18 BRCA1 NM_007294.4(BRCA1):c.4524G>A (p.Trp1508Ter) SNV Pathogenic 55221 rs80356885 GRCh37: 17:41226499-41226499
GRCh38: 17:43074482-43074482
19 BRCA1 NM_007294.4(BRCA1):c.4485-1G>A SNV Pathogenic 55213 rs80358189 GRCh37: 17:41226539-41226539
GRCh38: 17:43074522-43074522
20 BRCA1 NM_007294.4(BRCA1):c.3893C>A (p.Ser1298Ter) SNV Pathogenic 55039 rs80357440 GRCh37: 17:41243655-41243655
GRCh38: 17:43091638-43091638
21 BRCA1 NM_007294.4(BRCA1):c.3598C>T (p.Gln1200Ter) SNV Pathogenic 54929 rs62625307 GRCh37: 17:41243950-41243950
GRCh38: 17:43091933-43091933
22 BRCA1 NM_007294.4(BRCA1):c.241C>T (p.Gln81Ter) SNV Pathogenic 54565 rs80357350 GRCh37: 17:41256945-41256945
GRCh38: 17:43104928-43104928
23 BRCA1 NM_007294.4(BRCA1):c.131G>T (p.Cys44Phe) SNV Pathogenic 54200 rs80357446 GRCh37: 17:41267746-41267746
GRCh38: 17:43115729-43115729
24 BRCA2 NM_000059.4(BRCA2):c.6952C>T (p.Arg2318Ter) SNV Pathogenic 38076 rs80358920 GRCh37: 13:32920978-32920978
GRCh38: 13:32346841-32346841
25 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 GRCh37: 13:32954050-32954050
GRCh38: 13:32379913-32379913
26 PALB2 NM_024675.3(PALB2):c.3549C>A (p.Tyr1183Ter) SNV Pathogenic 128144 rs118203998 GRCh37: 16:23614792-23614792
GRCh38: 16:23603471-23603471
27 BRCA1 NM_007294.4(BRCA1):c.117T>A (p.Cys39Ter) SNV Pathogenic 479243 rs886040898 GRCh37: 17:41267760-41267760
GRCh38: 17:43115743-43115743
28 BRCA1 NM_007294.4(BRCA1):c.3G>T (p.Met1Ile) SNV Pathogenic 55072 rs80357475 GRCh37: 17:41276111-41276111
GRCh38: 17:43124094-43124094
29 TP53 NM_000546.5(TP53):c.559+1G>A SNV Pathogenic 428908 rs1131691042 GRCh37: 17:7578370-7578370
GRCh38: 17:7675052-7675052
30 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic 12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
31 TP53 NM_000546.5(TP53):c.96+1G>T SNV Pathogenic 482212 rs1131691003 GRCh37: 17:7579699-7579699
GRCh38: 17:7676381-7676381
32 SMAD4 NM_005359.5(SMAD4):c.1245_1248delCAGA (p.Asp415Glufs) Deletion Pathogenic 142253 rs80338965 GRCh37: 18:48593491-48593494
GRCh38: 18:51067121-51067124
33 PALB2 NM_024675.3(PALB2):c.2120del (p.Pro707fs) Deletion Pathogenic 128128 rs587780210 GRCh37: 16:23641355-23641355
GRCh38: 16:23630034-23630034
34 PALB2 NM_024675.4(PALB2):c.509_510del Deletion Pathogenic 126757 rs515726123 GRCh37: 16:23647357-23647358
GRCh38: 16:23636036-23636037
35 PALB2 NM_024675.3(PALB2):c.226del (p.Ile76fs) Deletion Pathogenic 142408 rs587782443 GRCh37: 16:23647641-23647641
GRCh38: 16:23636320-23636320
36 PALB2 NM_024675.4(PALB2):c.3114-1_3201+2del Deletion Pathogenic 1049345 GRCh37: 16:23625323-23625413
GRCh38: 16:23614002-23614092
37 PALB2 NM_024675.3(PALB2):c.3549C>G (p.Tyr1183Ter) SNV Pathogenic 1245 rs118203998 GRCh37: 16:23614792-23614792
GRCh38: 16:23603471-23603471
38 TSC1 , TMEM71 t(8;9)(q24.22;q34.13) Translocation Pathogenic 625198 GRCh37: 9:135791198-135791199
GRCh38:
39 PALB2 NM_024675.3(PALB2):c.1652dup (p.Tyr551Ter) Duplication Pathogenic 560017 rs1555461176 GRCh37: 16:23646214-23646215
GRCh38: 16:23634893-23634894
40 RBBP8 NM_002894.3(RBBP8):c.1009A>G (p.Lys337Glu) SNV Pathogenic 5824 rs121434388 GRCh37: 18:20572799-20572799
GRCh38: 18:22992836-22992836
41 STK11 NM_000455.4(STK11):c.108C>A (p.Tyr36Ter) SNV Pathogenic 7452 rs137853079 GRCh37: 19:1207020-1207020
GRCh38: 19:1207021-1207021
42 STK11 NM_000455.4(STK11):c.936del (p.Lys312fs) Deletion Pathogenic 7454 rs397518443 GRCh37: 19:1222997-1222997
GRCh38: 19:1222998-1222998
43 ACVR1B NM_004302.5(ACVR1B):c.1159_1163del (p.Asp387fs) Deletion Pathogenic 8227 rs387906389 GRCh37: 12:52380624-52380628
GRCh38: 12:51986840-51986844
44 ACVR1B NM_004302.5(ACVR1B):c.1262-502_1392+24del Deletion Pathogenic 8228 rs1555162597 GRCh37: 12:52385141-52385797
GRCh38: 12:51991357-51992013
45 SMAD4 NM_005359.6(SMAD4):c.1072G>T (p.Gly358Ter) SNV Pathogenic 8536 rs121912576 GRCh37: 18:48591909-48591909
GRCh38: 18:51065539-51065539
46 SMAD4 NM_005359.6(SMAD4):c.1477G>C (p.Asp493His) SNV Pathogenic 8538 rs121912578 GRCh37: 18:48604655-48604655
GRCh38: 18:51078285-51078285
47 SMAD4 NM_005359.6(SMAD4):c.1543A>T (p.Arg515Ter) SNV Pathogenic 8539 rs121912579 GRCh37: 18:48604721-48604721
GRCh38: 18:51078351-51078351
48 STK11 NM_000455.5(STK11):c.716G>A (p.Trp239Ter) SNV Pathogenic 931293 GRCh37: 19:1220698-1220698
GRCh38: 19:1220699-1220699
49 TP53 NM_001126118.1(TP53):c.-13G>T SNV Pathogenic 12371 rs121912661 GRCh37: 17:7579582-7579582
GRCh38: 17:7676264-7676264
50 STK11 NM_000455.4(STK11):c.650del (p.Pro217fs) Deletion Pathogenic 7453 rs397518442 GRCh37: 19:1220629-1220629
GRCh38: 19:1220630-1220630

Cosmic variations for Pancreatic Cancer:

9 (show top 50) (show all 355)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90142044 TRAF7 pancreas,NS,carcinoma,acinar carcinoma c.1187A>G p.Q396R 16:2173972-2173972 63
2 COSM84313984 TRAF2 pancreas,NS,carcinoma,acinar carcinoma c.876G>T p.E292D 9:136920431-136920431 63
3 COSM120694978 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 63
4 COSM121998482 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 63
5 COSM100986702 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 63
6 COSM92461094 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 63
7 COSM151944134 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
8 COSM151626276 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
9 COSM131023131 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
10 COSM111397487 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
11 COSM89661338 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
12 COSM151570633 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
13 COSM109739345 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
14 COSM151424813 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
15 COSM151524008 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
16 COSM149468859 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
17 COSM150576869 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
18 COSM106820556 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
19 COSM148672905 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
20 COSM112784932 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
21 COSM140844884 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
22 COSM151249776 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
23 COSM148061297 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
24 COSM138940468 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 63
25 COSM103090674 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1156G>C p.G386R 18:51067035-51067035 63
26 COSM139776915 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.868G>C p.G290R 18:51067035-51067035 63
27 COSM91386650 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1600C>T p.Q534* 18:51078408-51078408 63
28 COSM103083840 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1597C>A p.L533I 18:51078405-51078405 63
29 COSM103089012 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1600C>T p.Q534* 18:51078408-51078408 63
30 COSM139771981 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1309C>A p.L437I 18:51078405-51078405 63
31 COSM91381131 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1597C>A p.L533I 18:51078405-51078405 63
32 COSM139775765 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1312C>T p.Q438* 18:51078408-51078408 63
33 COSM91388156 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1156G>C p.G386R 18:51067035-51067035 63
34 COSM103029577 SETD2 pancreas,NS,carcinoma,acinar carcinoma c.4325C>A p.S1442* 3:47120311-47120311 63
35 COSM149744235 SETD2 pancreas,NS,carcinoma,acinar carcinoma c.-26C>A p.? 3:47120311-47120311 63
36 COSM137016084 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 63
37 COSM130781152 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 63
38 COSM88247526 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 63
39 COSM93826387 ROS1 pancreas,NS,carcinoma,acinar carcinoma c.5738C>A p.A1913D 6:117321280-117321280 63
40 COSM93857613 ROS1 pancreas,NS,carcinoma,acinar carcinoma c.5756C>A p.A1919D 6:117321280-117321280 63
41 COSM107060151 RARA pancreas,NS,carcinoma,acinar carcinoma c.704T>A p.I235N 17:40354489-40354489 63
42 COSM98725155 RARA pancreas,NS,carcinoma,acinar carcinoma c.1043T>A p.I348N 17:40354489-40354489 63
43 COSM98729090 RARA pancreas,NS,carcinoma,acinar carcinoma c.995T>A p.I332N 17:40354489-40354489 63
44 COSM107058842 RARA pancreas,NS,carcinoma,acinar carcinoma c.994G>T p.G332C 17:40356122-40356122 63
45 COSM86830145 RARA pancreas,NS,carcinoma,acinar carcinoma c.995T>A p.I332N 17:40354489-40354489 63
46 COSM98724291 RARA pancreas,NS,carcinoma,acinar carcinoma c.1333G>T p.G445C 17:40356122-40356122 63
47 COSM98728207 RARA pancreas,NS,carcinoma,acinar carcinoma c.1285G>T p.G429C 17:40356122-40356122 63
48 COSM86828778 RARA pancreas,NS,carcinoma,acinar carcinoma c.1285G>T p.G429C 17:40356122-40356122 63
49 COSM98707819 RARA pancreas,NS,carcinoma,acinar carcinoma c.1270G>T p.G424C 17:40356122-40356122 63
50 COSM98708620 RARA pancreas,NS,carcinoma,acinar carcinoma c.980T>A p.I327N 17:40354489-40354489 63

Copy number variations for Pancreatic Cancer from CNVD:

7 (show top 50) (show all 15981)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13839 1 100027661 100101597 Gain and loss AGL Pancreatic cancer
2 13849 1 100147561 100201027 Gain and loss SLC35A3 Pancreatic cancer
3 13857 1 100215810 100260948 Gain and loss MFSD14A Pancreatic cancer
4 13861 1 100261125 100310532 Gain and loss SASS6 Pancreatic cancer
5 13862 1 10027309 10175557 Gain and loss UBE4B Pancreatic cancer
6 13871 1 100326522 100355822 Gain and loss LRRC39 Pancreatic cancer
7 13875 1 100372897 100427397 Gain and loss DBT Pancreatic cancer
8 13880 1 100443784 100469348 Gain and loss RTCA Pancreatic cancer
9 13887 1 100530068 100697853 Gain and loss CDC14A Pancreatic cancer
10 13901 1 100715714 100719589 Gain and loss GPR88 Pancreatic cancer
11 13916 1 100897318 100916618 Gain and loss VCAM1 Pancreatic cancer
12 13924 1 101049969 101073575 Gain and loss EXTL2 Pancreatic cancer
13 13925 1 101073653 101157013 Gain and loss SLC30A7 Pancreatic cancer
14 13931 1 101167641 101203392 Gain and loss DPH5 Pancreatic cancer
15 13942 1 101414596 101419094 Gain and loss S1PR1 Pancreatic cancer
16 13966 1 101980154 102174569 Gain and loss OLFM3 Pancreatic cancer
17 13979 1 10205097 10375920 Gain and loss KIF1B Pancreatic cancer
18 14027 1 103055016 103286073 Gain and loss COL11A1 Pancreatic cancer
19 14059 1 103780424 103834168 Gain and loss RNPC3 Pancreatic cancer
20 14081 1 103871529 103880389 Gain and loss AMY2A Pancreatic cancer
21 14091 1 103910910 103919188 Gain and loss AMY1A Pancreatic cancer
22 14093 1 10393351 10414467 Gain and loss PGD Pancreatic cancer
23 14151 1 10424425 10446476 Gain and loss CENPS Pancreatic cancer
24 14168 1 10454871 10466879 Gain and loss DFFA Pancreatic cancer
25 14176 1 10469278 10625079 Gain and loss PEX14 Pancreatic cancer
26 14277 1 10641535 10790973 Gain and loss CASZ1 Pancreatic cancer
27 14348 1 107311380 107313956 Gain and loss PRMT6 Pancreatic cancer
28 14354 1 107395591 107665249 Gain and loss NTNG1 Pancreatic cancer
29 14396 1 107825832 108219580 Gain and loss VAV3 Pancreatic cancer
30 14412 1 107915304 108309068 Gain or loss VAV3 Pancreas cancer
31 14435 1 108389491 108454940 Gain and loss SLC25A24 Pancreatic cancer
32 14445 1 108477129 108498715 Gain and loss NBPF4 Pancreatic cancer
33 14472 1 108630504 108640564 Gain and loss NBPF5P Pancreatic cancer
34 14486 1 108815093 108889808 Gain and loss FAM102B Pancreatic cancer
35 14495 1 108947005 108956462 Gain and loss PRPF38B Pancreatic cancer
36 14496 1 108977028 108997407 Gain and loss FNDC7 Pancreatic cancer
37 14498 1 109001350 109064190 Gain and loss STXBP3 Pancreatic cancer
38 14509 1 109131869 109185060 Gain and loss GPSM2 Pancreatic cancer
39 14514 1 109184172 109218121 Gain and loss CLCC1 Pancreatic cancer
40 14518 1 109224882 109296777 Gain and loss WDR47 Pancreatic cancer
41 14530 1 109319187 109330611 Gain and loss TAF13 Pancreatic cancer
42 14538 1 109368575 109461639 Gain and loss ELAPOR1 Pancreatic cancer
43 14554 1 109468582 109492827 Gain and loss SARS1 Pancreatic cancer
44 14558 1 109504683 109530414 Gain and loss CELSR2 Pancreatic cancer
45 14588 1 109568465 109652615 Gain and loss SORT1 Pancreatic cancer
46 14603 1 109594163 109619901 Gain or loss CELSR2 Pancreas cancer
47 14615 1 109656520 109681079 Gain and loss PSMA5 Pancreatic cancer
48 14617 1 109721142 109734212 Gain and loss SYPL2 Pancreatic cancer
49 14619 1 109738603 109747396 Gain and loss ATXN7L2 Pancreatic cancer
50 14623 1 109748763 109755097 Gain and loss CYB561D1 Pancreatic cancer

Expression for Pancreatic Cancer

Search GEO for disease gene expression data for Pancreatic Cancer.

Pathways for Pancreatic Cancer

Pathways related to Pancreatic Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Pancreatic cancer hsa05212

Pathways related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 TSC1 TP53 STK11 KRAS BRCA1 ATM
2
Show member pathways
12.89 TSC1 TP53 STK11 RBBP8 BRCA1 ATM
3
Show member pathways
12.7 TP53 SMAD4 KRAS BRCA2 BRCA1
4
Show member pathways
12.61 TP53 KRAS BRCA2 BRCA1 ATM
5
Show member pathways
12.51 TSC1 TP53 KRAS BRCA2 BRCA1 ATM
6 12.39 TP53 RBBP8 BRCA2 BRCA1 ATM
7
Show member pathways
12.38 TP53 KRAS ATM ACVR1B
8
Show member pathways
12.29 TP53 SMAD4 ATM ACVR1B
9 12.27 TP53 SMAD4 KRAS ATM
10
Show member pathways
12.25 TP53 MIR221 MIR17 BRCA1 ATM
11 12.24 TP53 MIR21 MIR10A KRAS
12
Show member pathways
12.1 RBBP8 PALB2 BRCA2 BRCA1 ATM
13 12.06 TSC1 TP53 KRAS ATM
14
Show member pathways
12.03 TSC1 TP53 STK11 KRAS
15
Show member pathways
11.97 STK11 SMAD4 KRAS ATM
16
Show member pathways
11.94 RBBP8 PALB2 BRCA2 BRCA1 ATM
17 11.89 TP53 MIR483 MIR34A MIR221 MIR21 MIR17
18 11.86 TP53 SMAD4 KRAS ATM
19 11.81 PALB2 BRCA2 BRCA1
20
Show member pathways
11.77 TP53 BRCA1 ATM
21 11.75 TSC1 TP53 STK11 SMAD4 KRAS BRCA2
22 11.69 TP53 BRCA1 ATM
23 11.69 RBBP8 BRCA1 ATM
24 11.62 TP53 BRCA1 ATM
25 11.49 TP53 SMAD4 BRCA1
26 11.47 TP53 MIR221 ATM
27
Show member pathways
11.47 TP53 RBBP8 BRCA2 BRCA1 ATM
28 11.42 TP53 BRCA1 ATM
29 11.41 STK11 RBBP8 ATM
30 11.38 TP53 BRCA1 ATM
31 11.25 TSC1 TP53 STK11 SMAD4
32 11.19 TP53 BRCA1 ATM
33 11.02 TP53 RBBP8 BRCA1 ATM
34 10.91 TP53 BRCA1 ATM

GO Terms for Pancreatic Cancer

Cellular components related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.02 MIR34A MIR221 MIR21 MIR17 MIR15A

Biological processes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 10.12 TP53 STK11 RBBP8 BRCA2 BRCA1 ATM
2 DNA repair GO:0006281 10.06 RBBP8 PALB2 BRCA2 BRCA1 ATM
3 positive regulation of apoptotic process GO:0043065 10.04 TP53 MIR221 MIR21 MIR15A ATM
4 regulation of apoptotic process GO:0042981 10 TP53 MIR155 BRCA1 ATM
5 in utero embryonic development GO:0001701 9.98 TP53 SMAD4 PALB2 ACVR1B
6 regulation of cell proliferation GO:0042127 9.98 TP53 SMAD4 MIR155 BRCA1
7 negative regulation of gene expression GO:0010629 9.93 TP53 MIR34A MIR21 MIR17 MIR155 ACVR1B
8 cellular response to hypoxia GO:0071456 9.91 TP53 MIR34A MIR17 MIR155
9 negative regulation of cell proliferation GO:0008285 9.91 TSC1 TP53 STK11 SMAD4 MIR221 MIR21
10 negative regulation of angiogenesis GO:0016525 9.9 MIR34A MIR21 MIR15A MIR10A
11 negative regulation of cell growth GO:0030308 9.89 TP53 STK11 SMAD4 ACVR1B
12 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.88 MIR21 MIR15A MIR155
13 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.87 SMAD4 MIR221 MIR21
14 multicellular organism growth GO:0035264 9.87 TP53 PALB2 ATM
15 gene silencing by miRNA GO:0035195 9.86 MIR483 MIR34A MIR221 MIR21 MIR17 MIR15A
16 double-strand break repair GO:0006302 9.84 TP53 BRCA2 BRCA1
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.83 MIR221 MIR21 MIR17
18 response to ionizing radiation GO:0010212 9.83 STK11 BRCA1 ATM
19 somitogenesis GO:0001756 9.8 TP53 PALB2 ATM
20 positive regulation of epithelial to mesenchymal transition GO:0010718 9.8 SMAD4 MIR221 MIR21
21 regulation of signal transduction by p53 class mediator GO:1901796 9.8 TP53 STK11 RBBP8 BRCA1 ATM
22 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.79 BRCA2 BRCA1 ATM
23 negative regulation of sprouting angiogenesis GO:1903671 9.79 MIR34A MIR221 MIR17
24 positive regulation of cell cycle arrest GO:0071158 9.76 TP53 MIR34A BRCA1
25 cellular response to DNA damage stimulus GO:0006974 9.76 TP53 STK11 RBBP8 PALB2 MIR34A BRCA2
26 negative regulation of vascular endothelial growth factor production GO:1904046 9.75 MIR34A MIR17 MIR15A
27 positive regulation of transforming growth factor beta receptor signaling pathway GO:0030511 9.74 STK11 SMAD4 MIR21
28 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.73 MIR483 MIR15A MIR155
29 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.73 MIR483 MIR221 MIR15A MIR155
30 female gonad development GO:0008585 9.72 SMAD4 BRCA2 ATM
31 double-strand break repair via homologous recombination GO:0000724 9.72 RBBP8 PALB2 BRCA2 BRCA1 ATM
32 positive regulation of connective tissue replacement GO:1905205 9.71 MIR34A MIR155
33 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.71 MIR17 MIR155
34 inner cell mass cell proliferation GO:0001833 9.71 PALB2 BRCA2
35 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.71 MIR34A MIR21 MIR15A
36 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.7 MIR17 MIR155
37 negative regulation by host of viral genome replication GO:0044828 9.7 MIR221 MIR155
38 positive regulation of cellular senescence GO:2000774 9.7 MIR34A MIR10A KRAS
39 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.69 MIR221 MIR155
40 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.69 TP53 MIR34A MIR17
41 positive regulation of metalloendopeptidase activity GO:1904685 9.68 MIR21 MIR17
42 negative regulation of vascular wound healing GO:0061044 9.68 MIR34A MIR155
43 positive regulation of histone H3-K9 acetylation GO:2000617 9.67 SMAD4 BRCA1
44 negative regulation of regulatory T cell differentiation GO:0045590 9.67 MIR21 MIR155
45 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.67 TP53 BRCA2 BRCA1
46 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.66 MIR21 MIR17
47 DNA double-strand break processing GO:0000729 9.65 RBBP8 BRCA1 ATM
48 chordate embryonic development GO:0043009 9.64 BRCA2 BRCA1
49 negative regulation of interleukin-21 production GO:0032705 9.63 MIR221 MIR21
50 positive regulation of gene expression GO:0010628 9.56 TP53 MIR34A MIR21 MIR155 KRAS BRCA1

Molecular functions related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.35 TP53 MIR34A MIR21 MIR17 MIR15A
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR483 MIR34A MIR221 MIR21 MIR17 MIR15A
3 LRR domain binding GO:0030275 9.16 STK11 KRAS

Sources for Pancreatic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....